牛牛AI助理已提取核心訊息
On February 6, 2024, Processa Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, announced that it has regained compliance with the NASDAQ's minimum closing bid price requirement, thereby maintaining its listing on the Nasdaq Capital Market. The company's stock had to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which it successfully achieved by February 2, 2024. This compliance follows NASDAQ Listing Rule 5550(a)(2), also known as the Minimum Bid Price Rule. The announcement was made through a press release and marks the closure of the matter with NASDAQ. Processa Pharmaceuticals specializes in developing next-generation chemotherapy drugs aimed at improving the efficacy and safety of cancer treatments. The company is currently working on three next-generation chemotherapy treatments targeting various cancers, including breast, colorectal, and pancreatic cancers.
On February 6, 2024, Processa Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, announced that it has regained compliance with the NASDAQ's minimum closing bid price requirement, thereby maintaining its listing on the Nasdaq Capital Market. The company's stock had to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which it successfully achieved by February 2, 2024. This compliance follows NASDAQ Listing Rule 5550(a)(2), also known as the Minimum Bid Price Rule. The announcement was made through a press release and marks the closure of the matter with NASDAQ. Processa Pharmaceuticals specializes in developing next-generation chemotherapy drugs aimed at improving the efficacy and safety of cancer treatments. The company is currently working on three next-generation chemotherapy treatments targeting various cancers, including breast, colorectal, and pancreatic cancers.
2024年2月6日，處於臨床階段的製藥公司Processa Pharmicals, Inc. 宣佈已恢復遵守納斯達克的最低收盤價要求，從而維持其在納斯達克資本市場的上市。該公司的股票必須連續至少10個工作日維持在1.00美元或以上的最低收盤價，到2024年2月2日成功實現了這一目標。該合規遵循納斯達克上市規則5550（a）（2），也稱爲最低出價規則。該公告是通過新聞稿發佈的，標誌着此事與納斯達克的結案。Processa Pharmicals專門開發旨在提高癌症治療療效和安全性的下一代化療藥物。該公司目前正在研究三種針對各種癌症的下一代化療療法，包括乳腺癌、結直腸癌和胰腺癌。
2024年2月6日，處於臨床階段的製藥公司Processa Pharmicals, Inc. 宣佈已恢復遵守納斯達克的最低收盤價要求，從而維持其在納斯達克資本市場的上市。該公司的股票必須連續至少10個工作日維持在1.00美元或以上的最低收盤價，到2024年2月2日成功實現了這一目標。該合規遵循納斯達克上市規則5550（a）（2），也稱爲最低出價規則。該公告是通過新聞稿發佈的，標誌着此事與納斯達克的結案。Processa Pharmicals專門開發旨在提高癌症治療療效和安全性的下一代化療藥物。該公司目前正在研究三種針對各種癌症的下一代化療療法，包括乳腺癌、結直腸癌和胰腺癌。
有用
沒用